Literature DB >> 34004031

VGLL4 inhibits YAP1/TEAD signaling to suppress the epidermal squamous cell carcinoma cancer phenotype.

McKayla Mickle1, Gautam Adhikary1, Suruchi Shrestha1, Wen Xu1, Richard L Eckert1,2,3.   

Abstract

Epidermal squamous cell carcinoma (SCC) develops in response to ultraviolet light exposure and is among the most common cancers. The transglutaminase 2 cancer cell survival protein stimulates the activity of the YAP1/TEAD transcription complex to drive the expression of genes that promote aggressive epidermal SCC cell invasion, migration, and tumor formation. Therefore, we are interested in mechanisms that may inhibit these events. Vestigial-like protein-4 (VGLL4) is a transcription cofactor/tumor suppressor that inhibits several pro-cancer pathways including YAP1 signaling. Our present studies show that VGLL4 inhibits YAP1/TEAD-dependent transcription to reduce the expression of YAP1 target genes (CCND1, CYR61, and CTGF) and pro-cancer collagen genes (COL1A2 and COL3A1). We further show that loss of these YAP1 regulated genes is required for VGLL4 suppression of the cancer cell phenotype, as forced CCND1 or COL1A2 expression partially restores the aggressive cancer phenotype in VGLL4 expressing cells. Consistent with these findings, VGLL4 expression reduces tumor formation, and this is associated with reduced CCND1, CYR61, CTGF, COL1A2, and COL1A3 mRNA and protein levels, and reduced EMT marker expression. These findings indicate that VGLL4 suppresses the malignant epidermal SCC cancer phenotype by inhibiting YAP1/TEAD-dependent pro-cancer signaling.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  CCND1; COL1A2; COL3A1; CTFG; CYR61; Hippo signaling; TAZ; TEAD; YAP; cancer stem cell; epidermal squamous cell carcinoma; transglutaminase 2

Mesh:

Substances:

Year:  2021        PMID: 34004031      PMCID: PMC8243851          DOI: 10.1002/mc.23307

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   5.139


  51 in total

1.  Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1-adrenergic activation of gene expression in cardiac myocytes.

Authors:  Hsiao-Huei Chen; Steven J Mullett; Alexandre F R Stewart
Journal:  J Biol Chem       Date:  2004-05-12       Impact factor: 5.157

2.  Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.

Authors:  Matthew L Fisher; Jeffrey W Keillor; Wen Xu; Richard L Eckert; Candace Kerr
Journal:  Mol Cancer Res       Date:  2015-05-01       Impact factor: 5.852

3.  Involvement of CTGF, a hypertrophic chondrocyte-specific gene product, in tumor angiogenesis.

Authors:  T Shimo; T Nakanishi; T Nishida; M Asano; A Sasaki; M Kanyama; T Kuboki; T Matsumura; M Takigawa
Journal:  Oncology       Date:  2001       Impact factor: 2.935

Review 4.  The molecular basis that unifies the metabolism, cellular uptake and chemopreventive activities of dietary isothiocyanates.

Authors:  Yuesheng Zhang
Journal:  Carcinogenesis       Date:  2011-11-10       Impact factor: 4.944

5.  The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype.

Authors:  Sivaveera Kandasamy; Gautam Adhikary; Ellen A Rorke; Joseph S Friedberg; McKayla B Mickle; H Richard Alexander; Richard L Eckert
Journal:  Mol Cancer Res       Date:  2019-11-15       Impact factor: 5.852

6.  Transglutaminase Interaction with α6/β4-Integrin Stimulates YAP1-Dependent ΔNp63α Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation.

Authors:  Matthew L Fisher; Candace Kerr; Gautam Adhikary; Dan Grun; Wen Xu; Jeffrey W Keillor; Richard L Eckert
Journal:  Cancer Res       Date:  2016-10-25       Impact factor: 12.701

7.  VEGF-A acts via neuropilin-1 to enhance epidermal cancer stem cell survival and formation of aggressive and highly vascularized tumors.

Authors:  D Grun; G Adhikary; R L Eckert
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

8.  Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.

Authors:  Anupam Kumar; Jia Xu; Bokyung Sung; Santosh Kumar; Dihua Yu; Bharat B Aggarwal; Kapil Mehta
Journal:  Breast Cancer Res       Date:  2012-01-06       Impact factor: 6.466

9.  Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.

Authors:  Matthew L Fisher; Gautam Adhikary; Wen Xu; Candace Kerr; Jeffrey W Keillor; Richard L Eckert
Journal:  Oncotarget       Date:  2015-08-21

10.  Identification of COL1A1 and COL1A2 as candidate prognostic factors in gastric cancer.

Authors:  Jun Li; Yuemin Ding; Aiqing Li
Journal:  World J Surg Oncol       Date:  2016-11-29       Impact factor: 2.754

View more
  3 in total

1.  [Metformin inhibits proliferation and promotes apoptosis of HER-2 positive breast cancer cells possibly through the Hippo-YAP pathway].

Authors:  Y Xu; T Xu; Y Xiong; J Huang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-05-20

Review 2.  Investigating Cutaneous Squamous Cell Carcinoma in vitro and in vivo: Novel 3D Tools and Animal Models.

Authors:  Marika Quadri; Alessandra Marconi; Simran K Sandhu; Alexi Kiss; Tatiana Efimova; Elisabetta Palazzo
Journal:  Front Med (Lausanne)       Date:  2022-05-09

3.  Myosin light chain 9 promotes the proliferation, invasion, migration and angiogenesis of colorectal cancer cells by binding to Yes-associated protein 1 and regulating Hippo signaling.

Authors:  Min Feng; Ningfei Dong; Xin Zhou; Lihong Ma; Rui Xiang
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.